



## first generations

tricyclic & tetracyclic amines (TCA)




tricyclic amines (TCA)

What are the common, key features?





antidepressants origins

## first generations monoamine oxidase inhibitors




antidepressants origins

## second generations phenoxyphenylpropylamines

**R**


type &amp; position are critical

R=	inhibition of reuptake (K <sub>i</sub> nM)	
	5-HT	NE
H	102	200
2-OCH <sub>3</sub>	1371	2.4
2-SCH <sub>3</sub>	130	0.2
2-CH <sub>3</sub>	390	3.4
4-CH <sub>3</sub>	95	570
4-OCH <sub>3</sub>	71	1207
2-CF <sub>3</sub>	1489	4467
3-CF <sub>3</sub>	16	1328
4-CF <sub>3</sub>	17	2703
4-CF <sub>3</sub> , NH <sub>2</sub>	17	2703

**R**

type &amp; position are critical

R=	inhibition of reuptake (K <sub>i</sub> nM)	
	5-HT	NE
H	102	200
2-OCH <sub>3</sub>	1371	2.4
2-SCH <sub>3</sub>	130	0.2
2-CH <sub>3</sub>	390	3.4
4-CH <sub>3</sub>	95	570
4-OCH <sub>3</sub>	71	1207
2-CF <sub>3</sub>	1489	4467
3-CF <sub>3</sub>	16	1328
4-CF <sub>3</sub>	17	2703
4-CF <sub>3</sub> , NH <sub>2</sub>	17	2703




# R

**R** type & position are critical

inhibition of  
reuptake ( $K_i$  nM)

R=	5-HT	NE
H	102	200
2-OCH <sub>3</sub>	1371	2.4
2-SCH <sub>3</sub>	130	0.2
2-CH <sub>3</sub>	390	3.4
4-CH <sub>3</sub>	95	570
4-OCH <sub>3</sub>	71	1207
2-CF <sub>3</sub>	1489	4467
3-CF <sub>3</sub>	16	1328
4-CF <sub>3</sub>	17	2703
4-CF <sub>3</sub> , NH <sub>2</sub>	17	2703

2-substituted analogues are weak SSRI,  
but potent & selective towards NE reuptake




# R

**R** type & position are critical

inhibition of  
reuptake ( $K_i$  nM)

R=	5-HT	NE
H	102	200
2-OCH <sub>3</sub>	1371	2.4
2-SCH <sub>3</sub>	130	0.2
2-CH <sub>3</sub>	390	3.4
4-CH <sub>3</sub>	95	570
4-OCH <sub>3</sub>	71	1207
2-CF <sub>3</sub>	1489	4467
3-CF <sub>3</sub>	16	1328
4-CF <sub>3</sub>	17	2703
4-CF <sub>3</sub> , NH <sub>2</sub>	17	2703

2-CH<sub>3</sub> : weak SSRI;  
4-CH<sub>3</sub> : better potency & selectivity towards 5-HT reuptake blockade



# R

**R** type & position are critical

inhibition of  
reuptake ( $K_i$  nM)

R=	5-HT	NE
H	102	200
2-OCH <sub>3</sub>	1371	2.4
2-SCH <sub>3</sub>	130	0.2
2-CH <sub>3</sub>	390	3.4
4-CH <sub>3</sub>	95	570
4-OCH <sub>3</sub>	71	1207
2-CF <sub>3</sub>	1489	4467
3-CF <sub>3</sub>	16	1328
4-CF <sub>3</sub>	17	2703
4-CF <sub>3</sub> , NH <sub>2</sub>	17	2703


2-CH<sub>3</sub> : weak SSRI;  
4-CH<sub>3</sub> : better potency & selectivity towards 5-HT reuptake blockade

as SSRI

also, 2-OCH<sub>3</sub><<<4-OCH<sub>3</sub>

Ortho substitution

may act as conformational blocker - better binding to NE transporter



# R

**R** type & position are critical

inhibition of  
reuptake ( $K_i$  nM)

R=	5-HT	NE
H	102	200
2-OCH <sub>3</sub>	1371	2.4
2-SCH <sub>3</sub>	130	0.2
2-CH <sub>3</sub>	390	3.4
4-CH <sub>3</sub>	95	570
4-OCH <sub>3</sub>	71	1207
* 2-CF <sub>3</sub>	1489	4467
* 3-CF <sub>3</sub>	16	1328
fluoxetine * 4-CF <sub>3</sub>	17	2703
norfluoxetine 4-CF <sub>3</sub> , NH <sub>2</sub>	17	2703

AS SSRI,  
4-CF<sub>3</sub>≈3-CF<sub>3">>>>2-CF<sub>3</sub></sub>

s-fluoxetine, 100X selective as ssRI than R-isomer

phenoxyphenylpropylamines

